

DR. RUTH ALON



Ms. Ruti Alon joined Pitango in 1997. With over 25 years of international experience in the high-tech medical industry, Ruti is a General Partner investing in life sciences companies. Pitango is Israel's largest Venture Capital fund with approximately \$1.3 billion under management.

Ms. Alon previously worked on Wall Street where she held senior positions with Montgomery Securities and Kidder Peabody & Co. As a senior medical device analyst, she was rated as one of the top in her field for four consecutive years. She also managed her own independent consulting business in San Francisco, providing broad-based services to early-stage companies and venture capitalists in the medical devices industry.

Ms. Alon is the force behind the establishment in 2005 of ILSI, Israel Life Science Industry, a non-for-profit organization representing the mutual goals of approximately 800 Israeli life science companies. She is the current Chairperson of ILSI.

Ruti has a B.A. in Economics from the Hebrew University of Jerusalem, an M.B.A. from Boston University, and a M.Sc. from Columbia University School of Physicians and Surgeons.

Ms. Alon currently is the Chairperson of the Board of Directors of BioControl, BrainsGate and TransPharma Medical. In addition, she is a member of the Boards of numerous Pitango portfolio companies including, BetaO₂, BioLineRx, Ventor, D-Pharm and HealOr. Over the past few years, Pitango has enjoyed several exits - ColBar, Disc-O-Tech were each acquired by large international corporations, BioControl Medical sold its Urological Division and BiolineRx went Public on the TASE. Most recently, Ventor Technologies where Ms. Alon served on the Board of Directors. was acquired by Medtronic, Inc. (NYSE: MDT)